Table 2.

Frequency of SSc-specific autoantibodies in the different ethnic groups. Values are % (n) unless otherwise specified.

AutoantibodyEntire Cohort, n = 1000African American, n = 228White, n = 555Hispanic, n = 196Other*, n = 21p
ACA22.0 (220)6.6 (15)1,329.2 (162)1,619.4 (38)3,623.8 (5)< 0.0001
Scl-70**21.3 (213)26.8 (61)218.0 (100)224.0 (47)23.8 (5)0.04
RNAP III**16.8 (168)14.0 (32)16.6 (92)20.9 (41)14.3 (3)NS
U3-RNP7.8 (78)22.8 (52)1,41.8 (10)1,56.1 (12) 4,519.1 (4)< 0.0001
Th/To3.9 (39)1.8 (4)4.5 (25)4.0 (8)9.5 (2)NS
PM/Scl2.2 (22)0.9 (2)2.9 (16)2.0 (4)0 (0)NS
More than 11.2 (12)0.9 (2)1.1 (6)2.0 (4)0 (0)NS
Undefined19.7 (197)21.9 (50)20.0 (111)17.9 (35)4.8 (1)NS
ANA−6.1 (61)***5.7 (13)***6.7 (37)***5.1 (10)***4.8 (1)NS
  • * Excluded in statistical analyses.

  • ** Includes 4 samples that were negative by immunodiffusion or ELISA, but positive by immunoprecipitation.

  • *** There are 10 overlapping RNAP III and ANA− samples (3 African American, 4 white, and 3 Hispanic). African American versus white:

  • 1 p < 0.0001 (ACA and U3-RNP),

  • 2 p = 0.008 (Scl-70). African American versus Hispanic:

  • 3 p < 0.0001 (ACA),

  • 4 p = 0.033 (U3-RNP). White versus Hispanic:

  • 5 p < 0.0001 (U3-RNP),

  • 6 p = 0.007 (ACA). No other significant differences in antibody prevalence were detected between any 2 ethnic groups. ANA+ samples negative for ACA, Scl-70, RNAP III, U3-RNP, Th/To, and PM/Scl were classified as undefined. SSc: systemic sclerosis; ACA: anticentromere antibodies; RNAP III: RNA polymerase III antibodies; ANA: antinuclear antibodies; NS: not significant.